Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Shares Spike for Second Time in a Week

NEW YORK (GenomeWeb News) – Shares of Compugen jumped 35 percent in early Monday trade on the Nasdaq after the firm announced that it had a new drug target for multiple epithelial tumors using its Monoclonal Antibody Targets Discovery Platform.

The firm's stock rose $1.42 to $5.50 within the first 20 minutes of the market's open. It was the second such spike in Compugen's stock within the past week.

Last week, its shares rose 62 percent in one day after it announced a deal to screen peptide candidates for three Pfizer drug targets.

Compugen said today that the new drug target, CGEN-671, is a membrane splice variant of CD55, a known drug target for gastric cancer for which monoclonal antibody therapies are in clinical development by others. It said that it has already filed patent applications covering the splice variant and its various therapeutic and diagnostic uses.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.